- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Introduction: Background on Hospital Readmissions
During the introduction to this one-on-one interview series, Arthur Garson, Jr, MD, MPH, director of the Center for Health Policy at the University of Virginia, discusses rates of hospital readmissions following transitions between healthcare settings and highlights a Centers for Medicare & Medicaid Services (CMS) program designed to reduce the number of readmissions.
Dr Garson, Jr, reviews the number of unnecessary hospital readmissions within 30 days of discharge and notes that nearly 20% of Medicare patients are readmitted.
However, he explains that the number of readmissions has recently decreased due to penalties implemented by a CMS program.
Dr Garson, Jr, emphasizes the importance of implementing programs that target readmissions such as the program designed by the CMS, and suggests that this program represents a step in the right direction toward reducing or preventing unnecessary hospital readmissions.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
